Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Republican Research and Practical Center for Epidemiology and Microbiology
With
Belarusian State Medical University
The trial evaluates the safety and efficacy of dendritic cell Immunotherapy for the patients with pancreatic cancer. Dendritic cells are obtained from blood monocytes using standard protocol.
Two options for dendritic cell priming are used: MUC-1/WT-1 peptides for the patients with unresectable tumor and/or tumor lysates for the patients undergoing tumor resection.
The dendritic cells are them matured and injected subcutaneous (all patients) and intratumorally (when possible).
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically confirmed pancreatic cancer (adenocarcinoma);
